How is VZVC different from a typical VC firm?

VZVC makes about five concentrated investments per year instead of dozens, has no associates (AI agents handle that role), and the investment team is just the two co-founders.

Why does Pande think AI can improve drug development?

He says AI can help identify drug targets, design drugs, and assist in clinical trials. He believes AI models will be much better than animal models at predicting human responses, which is key because only 20% of drugs succeed from first to third trial.

AI in HealthcareAI Business & IndustryTechCrunch AIAug 29, 2026Aug 30, 2026, 04:00 JST

Vijay Pande leaves a16z to launch small AI-focused VC firm

Send on LINE

3 Key Points

What happened
Vijay Pande, who grew a16z's healthcare practice to manage close to $4 billion, left last June to co-found VZVC with Zach Werner. The new firm makes about five concentrated bets a year instead of 30.
Why it matters
Pande argues biology is becoming an engineering discipline, where AI can design drugs and even run trials. He says the failure rate for drugs is high (only 20% succeed from first to third trial) because animal models aren't predictive of humans, and AI could be better.
What to watch
VZVC relies on AI agents instead of hiring associates, so the investment team is just Pande and Werner. Pande is focusing on AI for healthcare delivery and AI for clinical trials, and expects founder relationships to last 5 to 10 years plus.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Get news like this every morning, free

Context & Analysis

Pande's move reflects a broader shift in bio investing toward concentrated, hands-on approaches. After a decade at a16z, he now favors small teams and deeper involvement, citing inspirations like Antonio Gracias and Thrive. He sees AI as transforming biology from discovery to engineering, but warns that AI can't overcome missing data — a key challenge in biology where data isn't publicly scrapable. His firm's use of AI agents instead of associates is a notable experiment in operational efficiency.

The exit from a16z, where he managed close to $4 billion, came last June. His new firm, VZVC, is intentionally small, with just him and Werner, and about five bets per year. He emphasizes close, long-term relationships with founders, expecting them to last 5 to 10 years plus. This model avoids competing for hot rounds, as people make room for them.

Pande's focus areas are AI for healthcare delivery and AI for clinical trials. He believes AI can help personalise medicine, comparing an individual's data to themselves rather than population averages. However, he cautions against hype: AI can find insights humans can't, but if data is lacking, AI can't magically solve the problem.

FAQ

How is VZVC different from a typical VC firm?: VZVC makes about five concentrated investments per year instead of dozens, has no associates (AI agents handle that role), and the investment team is just the two co-founders.
Why does Pande think AI can improve drug development?: He says AI can help identify drug targets, design drugs, and assist in clinical trials. He believes AI models will be much better than animal models at predicting human responses, which is key because only 20% of drugs succeed from first to third trial.

TechCrunch AIRead Original Article

Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.